Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1618-7601
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations ; day:23 ; month:4 ; year:2020 ; pages:1-13
The European journal of health economics ; (23.4.2020), 1-13
- Creator
-
Westerink, Lotte
Nicolai, Jelmer L. J.
Samuelsen, Carl
Smit, Hans J. M.
Postmus, Pieter E.
Griebsch, Ingolf
Postma, Maarten J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10198-020-01186-9
- URN
-
urn:nbn:de:101:1-2020070403584125938962
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Westerink, Lotte
- Nicolai, Jelmer L. J.
- Samuelsen, Carl
- Smit, Hans J. M.
- Postmus, Pieter E.
- Griebsch, Ingolf
- Postma, Maarten J.
- SpringerLink (Online service)
Other Objects (12)
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Human scent as a first-line defense against disease
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Human scent as a first-line defense against disease
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma
AIH Therapy: Beyond First-Line
Tongue as a first-line immune organ?
Humoral First-Line Mucosal Innate Defence in vivo
Challenges to replace ACT as first-line drug
Correction to: Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Human scent as a first-line defense against disease
Medication beliefs in first-line and second-line treated multiple sclerosis patients
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Implementing Human Resource Management successfully: A first-line management challenge
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer